Further testing of candidate elements in transgenic assays will be needed to validate this possibility.
However, more assays will be needed in order to demonstrate and enhance their efficacy.
Experimental assays will be needed to define if the type III-hemolysin has a lytic role in vivo.
Further experimentation, employing biochemical and immuno-histochemical analysis of the identified proteins, in conjunction with enzyme assays, will be needed to dissect the precise physiological functions of these xylem sap proteins.
Additional assays, however, will be needed to demonstrate that the current LAVA element is still able to retrotranspose, and at what rate.
Since glandular homogenates were used for these assays, further studies will be needed to determine whether apoptosis is increased in the epithelium, the stroma or both compartments of aging VDRKO mice.
Better assays and biomarkers will be needed to interrogate the early treatment responses so that combinations can be rapidly personalised before resistance ensues.
23 In order to carry out these trials, the development of a validated assay to detect GR expression will be needed to identify patients who are most likely to benefit from treatment.
EM and immunoaffinity assays, likely using pooled samples, will be needed to identify the various sources and types of particles found in the cervicovaginal compartment sources, we would note, that might include the microbiome, not just the host.
Yet, in spite of these important findings, a major practical limitation is that biopsies for risk biomarker assessment are unlikely to be routinely implemented, and that therefore non-invasive methods will be needed to assay specific AGEs in skin.
